^
    4years
    [VIRTUAL] Response to Afatinib in a Patient with NSCLC Harboring Novel EGFR Exon 20 Insertion Mutations (IASLC-WCLC 2020)
    Based on this finding, afatinib might be considered as an optimal treatment for NSCLC harboring uncommon EGFR exon 20 insertion mutations. Further investigations need to be carried out.
    Clinical
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR exon 20 insertion • EGFR exon 20 mutation • EGFR N771delinsKG
    |
    Gilotrif (afatinib)